InvestorsHub Logo
Followers 7
Posts 754
Boards Moderated 0
Alias Born 03/11/2020

Re: Ganz post# 1496

Wednesday, 09/30/2020 10:57:24 AM

Wednesday, September 30, 2020 10:57:24 AM

Post# of 3573
News today,pretty much what the CFO told me ...

Cassava Sciences is currently conducting a long-term, open-label, multi-center study of sumifilam 100 mg twice-daily for 12 months. The study's target enrollment is approximately 100 patients with mild-to-moderate Alzheimer's disease. This study is over 50% enrolled.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SAVA News